San Francisco

EarthCam Premieres Sixth-Generation Autodesk Construction Cloud Integration

Retrieved on: 
Wednesday, September 28, 2022

New Orleans, Louisiana, Sept. 28, 2022 (GLOBE NEWSWIRE) -- EarthCam, the leader in live camera technology, content and services, released important upgrades to its Autodesk Construction Cloud integration today at Autodesk University.

Key Points: 
  • New Orleans, Louisiana, Sept. 28, 2022 (GLOBE NEWSWIRE) -- EarthCam, the leader in live camera technology, content and services, released important upgrades to its Autodesk Construction Cloud integration today at Autodesk University.
  • Through their long history of collaboration with Autodesk, EarthCam recently became the first camera company to be recognized as a Construction Cloud Premium Partner.
  • Integrating imagery and reports from EarthCam directly with Autodesk Construction Cloud empowers project managers to make informed decisions, mitigate risk and avoid project delays.
  • Autodesk, Autodesk Construction Cloud, BIM 360, Navisworks, PlanGrid, and Revit are registered trademarks or trademarks of Autodesk, Inc., in the USA and/or other countries.

Whiskey & Wine Reunite in Sagamore Spirit's Latest Reserve Series Release: Sherry Finish Rye Whiskey

Retrieved on: 
Tuesday, September 27, 2022

BALTIMORE, Sept. 27, 2022 /PRNewswire/ -- PX Sherry wine from Spanish vineyards and golden brown rye whiskey in Maryland's distinct, approachable style are coming together once again in a limited-edition Sagamore Spirit Reserve Series Sherry Finish Rye Whiskey, announced today by the award-winning distiller.

Key Points: 
  • The structured oak profile of Sagamore Spirit's whiskey balances the bouquet of dried fruit and honey left from the PX Sherry wine, creating a complex, yet approachable, 106-proof rye.
  • Sherry Finish is part of the Sagamore Spirit Reserve Series, a collection of limited-edition Maryland-style rye whiskies that celebrate the legacy of Maryland distilling, with an unyielding focus on excellence from start to finish.
  • This year's Sagamore Spirit Sherry Finish Rye Whiskey is as versatile as its predecessor.
  • To learn more about Sagamore Spirit's core expressions, including Cask Strength Rye Whiskey and Double Oak Rye Whiskey, as well as limited-time Reserve Series releases, visit www.SagamoreSpirit.com .

Eclipsebio Expands Intellectual Property Portfolio to Support New Product Suites Designed to Probe RNA Structure and Reveal Ribosome Occupancy and RNA Modifications

Retrieved on: 
Tuesday, September 27, 2022

This IP supports three key product suites, m6A-eCLIP for profiling m6A modifications, SHAPE for RNA structure probing, and Aurora for ribosome profiling.

Key Points: 
  • This IP supports three key product suites, m6A-eCLIP for profiling m6A modifications, SHAPE for RNA structure probing, and Aurora for ribosome profiling.
  • "This expansion of Eclipsebio's intellectual property portfolio supports the company's development of high-resolution, multi-dimensional RNA genomics technologies and product suites," said Peter Chu, Ph.D., CEO and cofounder of Eclipsebio.
  • Data derived from SHAPE RNA structure probing yields information that helps guide a more accurate RNA fold, an important parameter in developing RNA therapeutics.
  • For ribosome profiling, Eclipsebio is launching the Aurora products to provide a means of accurately quantifying ribosome occupancy and mapping ribosome position on mRNAs in cells.

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

Retrieved on: 
Monday, September 26, 2022

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.
  • Mayank is an accomplished leader with extensive experience in the biopharmaceutical industry including corporate development, partnering, product development and commercialization, said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Mayank will be instrumental in maximizing the value of tomivosertib and zotatifin as both compounds advance in clinical development.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

Retrieved on: 
Friday, September 23, 2022

Eighteen of the enrolled participants have already completed the 8-week treatment in accordance with the study design.

Key Points: 
  • Eighteen of the enrolled participants have already completed the 8-week treatment in accordance with the study design.
  • Part 1 of the Phase II study of ABV-1505 was conducted at UCSF from January 2020 through July 2020 and was accepted by the US Food & Drug Administration in October of 2020.
  • We are also delighted that the University of California, San Francisco is involved in the Phase II Part 2 study.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

SPIN ELECTRIC SCOOTER WORKERS OF BERKELEY JOIN TEAMSTERS LOCAL 665

Retrieved on: 
Friday, September 23, 2022

BERKELEY, Calif., Sept. 23, 2022 /PRNewswire/ -- Operations Specialists and Maintenance Specialists working for Spin electric scooters in Berkeley joined Teamsters Local 665 yesterday. The move came after the company agreed to voluntarily recognize Local 665 as the workers' collective bargaining representative via card check neutrality in a ceremony overseen by the city's mayor, Jesse Arreguín.

Key Points: 
  • BERKELEY, Calif., Sept. 23, 2022 /PRNewswire/ -- Operations Specialists and Maintenance Specialists working for Spin electric scooters in Berkeley joined Teamsters Local 665 yesterday.
  • The move came after the company agreed to voluntarily recognize Local 665 as the workers' collective bargaining representative via card check neutrality in a ceremony overseen by the city's mayor, Jesse Arregun.
  • "The workers at Spin of San Francisco already have a great collective bargaining agreement with the Teamsters," said Tony Delorio, Local 665 Secretary-Treasurer.
  • Teamsters Local 665 represents over 5,000 members throughout the Bay Area in waste management, transportation, and a wide variety of other industries.

Expansion and Growth - Lystek Fairfield OMRC Executes Three Major Agreements for Biosolids Delivery and Processing

Retrieved on: 
Thursday, September 22, 2022

CAMBRIDGE, Ontario and FAIRFIELD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- LYSTEK INTERNATIONAL is excited to announce significant expansion and growth at its US flagship facility in California. The Lystek Fairfield Organic Material Recovery Center (OMRC) has executed three new agreements for biosolids delivery and processing. The OMRC is a San Francisco Bay Area regional recycling facility that uses Lystek’s patented THP to process biosolids and organic materials into a high-nutrient fertilizer for agriculture and beneficial uses. California wastewater utilities are under increasing regulatory requirements to divert organics, such as biosolids, to facilities that can provide recycling and beneficial use end products.

Key Points: 
  • The Lystek Fairfield Organic Material Recovery Center (OMRC) has executed three new agreements for biosolids delivery and processing.
  • Rebecca Overacre, EBMUD Biosolids Program Manager, says, East Bay Municipal Utility District will use this agreement with Lystek to diversify its biosolids management program.
  • These three agreements add to the 10 regional customers that use the Fairfield OMRC for their biosolids or organic diversion needs.
  • Lystek offers turnkey solutions including technology supply, design-build and installation services, regional processing solutions, and comprehensive LysteGro product management .

2022 Evolution of Psychotherapy Orlando conference features masters, breakout thinkers in refreshed educational program

Retrieved on: 
Wednesday, September 21, 2022

MALVERN, Pa., Sept. 21, 2022 /PRNewswire-PRWeb/ -- This year's Evolution of Psychotherapy meeting welcomes back the masters of psychotherapy and welcomes new presenters to discuss emerging, future-focused topics that expand on the fundamentals of effective care.

Key Points: 
  • MALVERN, Pa., Sept. 21, 2022 /PRNewswire-PRWeb/ -- This year's Evolution of Psychotherapy meeting welcomes back the masters of psychotherapy and welcomes new presenters to discuss emerging, future-focused topics that expand on the fundamentals of effective care.
  • Dubbed the "Woodstock of Psychotherapy" by TIME magazine in 1985, the meeting allows established experts, forward thinkers, and on-the-ground professionals to connect, engage, support, and reinvigorate their practice in the field of psychotherapy.
  • "This year at Evolution of Psychotherapy Orlando, we are embracing what an evolution truly means: to change, develop, and grow," said Jeffrey Zeig, PhD, conference chairman and director and founder of The Milton H. Erickson Foundation.
  • The educational program features a returning core group of more than 20 world-renowned faculty, providing an experience familiar to past attendees.

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

Retrieved on: 
Wednesday, September 21, 2022

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

Key Points: 
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

Retrieved on: 
Tuesday, September 20, 2022

and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .

Key Points: 
  • and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .
  • I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk, said Dr. von Jako.
  • Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay.
  • NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person.